Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 16/20 | 0.71 |
| ▸ | ROCK2 | O75116 | 14/20 | 0.71 |
| ▸ | POLB | P06746 | 1/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | PDE5A | O76074 | 1/20 | 0.61 |
| ▸ | PRKACA | P17612 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2752637 | 0.94 | POLB (0.73) | ROCK1ROCK2POLBPDE5A | |
| SCHEMBL13357606 | 0.83 | ROCK1 (0.70) | ROCK1ROCK2LMNASMN1; SMN2PRKACA | |
| SCHEMBL2557811 | 0.83 | ROCK1 (1.00) | ROCK1ROCK2 | |
| SCHEMBL14738781 | 0.83 | ROCK1 (1.00) | ROCK1ROCK2 | |
| SCHEMBL2561029 | 0.83 | ROCK1 (1.00) | ROCK1ROCK2 | |
| SCHEMBL13357625 | 0.82 | ROCK1 (0.66) | ROCK1ROCK2PRKACA | |
| SCHEMBL2752587 | 0.82 | ROCK1 (0.69) | ROCK1ROCK2LMNAPRKACA | |
| SCHEMBL5184586 | 0.82 | GSTO1 (0.57) | ROCK1ROCK2POLBHTT | |
| SCHEMBL3257615 | 0.82 | ROCK1 (0.68) | ROCK1ROCK2LMNASMN1; SMN2PRKACA | |
| SCHEMBL13357658 | 0.82 | ROCK1 (0.68) | ROCK1ROCK2LMNASMN1; SMN2PRKACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160228414-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED | 2016-08-11 | — | — | US | disclosed |
| US-9249131-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-02-02 | — | — | US | disclosed |
| US-20150025076-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED | 2015-01-22 | — | — | US | disclosed |
| US-8853415-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-10-07 | — | — | US | disclosed |
| US-8741939-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-06-03 | — | — | US | disclosed |
| US-20140072995-A1 | Modulators of ATP-Binding Cassette Transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-03-13 | — | — | US | disclosed |
| US-8431605-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICAL INCORPORATED (US) | 2013-04-30 | — | — | US | disclosed |
| US-20120004216-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160228414-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCF1 | ROCK1 4299/4885ROCK2 4094/4885POLB 1440/4885 |
| US-20120004216-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCF1 | ROCK1 4299/4885ROCK2 4094/4885POLB 1440/4885 |
| US-20150025076-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCF1 | ROCK1 4257/4885ROCK2 4061/4885POLB 1494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.